This “Diabetic Neuropathic Pain - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Diabetic Neuropathic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DNP commonly causes burning, tingling, shooting, or electric shock-like sensations, usually starting in the feet or hands and worsening at night. Symptoms include severe pain, numbness, extreme sensitivity to touch (allodynia), muscle weakness, and potential issues with digestion or cardiovascular, and urinary functions.
The pathogenesis of DNP is not fully understood. Several theories have been proposed to explain the pain related to diabetic neuropathy, including microvascular damage to the blood vessels supplying peripheral nerves, metabolic and autoimmune disturbances accompanied by glial cell activation, alterations in sodium and calcium channel expression, and central pain mechanisms such as increased thalamic vascularity and imbalance in facilitatory and inhibitory descending pathways. Chronic hyperglycemia plays a central role by activating metabolic pathways such as the polyol pathway, leading to depletion of antioxidant defenses, increased oxidative and nitrosative stress, and accumulation of advanced glycation end products, all of which contribute to neuronal injury. Microvascular dysfunction further exacerbates nerve damage by causing ischemia, reduced perfusion, and hypoxia within the endoneurium, resulting in axonal degeneration and demyelination. In parallel, changes in ion channel expression particularly upregulation of voltage-gated sodium channels and dysregulation of calcium and potassium channels lead to neuronal hyperexcitability and abnormal pain signaling. Peripheral nerve injury also triggers activation of glial cells, promoting the release of pro-inflammatory cytokines and amplifying neuroinflammation. At the central level, sensitization of spinal neurons and enhanced glutamatergic signaling, along with reduced inhibitory GABAergic activity, contribute to heightened pain perception.
Diagnosis and management of DNP remain challenging due to incomplete understanding of its pathophysiology and limited disease-modifying therapies. Diagnosis is primarily clinical, involving a detailed history of symptoms such as burning, tingling, or shooting pain, along with neurological examination to assess sensory loss, reflexes, and nerve function, while excluding other causes of peripheral neuropathy. In some cases, nerve conduction studies or quantitative sensory testing may be used to confirm the diagnosis. Management begins with optimizing glycemic control and addressing lifestyle factors to slow disease progression. Pharmacological treatment is the mainstay, with first-line agents including anticonvulsants (pregabalin, gabapentin) and antidepressants (duloxetine, tricyclic antidepressants), which help reduce pain and improve sleep and quality of life. However, pain relief is often partial, with about 50% reduction considered successful. Opioids such as tramadol and tapentadol are reserved as second- or third-line options due to safety concerns. Topical therapies like capsaicin and lidocaine patches provide localized relief with fewer systemic effects. Adjunct treatments such as alpha-lipoic acid may offer additional benefits through antioxidant effects.
"Diabetic Neuropathic Pain - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathic Pain pipeline landscape is provided which includes the disease overview and Diabetic Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Further product details are provided in the report……..
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Diabetic Neuropathic Pain: Understanding
Diabetic Neuropathic Pain: Overview
Diabetic neuropathic pain (DNP) is characterized by tingling, burning, sharp, shooting, and lancinating or even as electric shock sensations. It is usually considered moderate to severe and often worse at night, causing sleeping disturbs. The pain can be constant and accompanied of cutaneous allodynia, which can substantially affect the quality of life of patients, impacting the ability to perform daily activities and having a negative influence on mood. The pain may also be a reason of withdrawal of recreational and social activities and may be associated with depression.DNP commonly causes burning, tingling, shooting, or electric shock-like sensations, usually starting in the feet or hands and worsening at night. Symptoms include severe pain, numbness, extreme sensitivity to touch (allodynia), muscle weakness, and potential issues with digestion or cardiovascular, and urinary functions.
The pathogenesis of DNP is not fully understood. Several theories have been proposed to explain the pain related to diabetic neuropathy, including microvascular damage to the blood vessels supplying peripheral nerves, metabolic and autoimmune disturbances accompanied by glial cell activation, alterations in sodium and calcium channel expression, and central pain mechanisms such as increased thalamic vascularity and imbalance in facilitatory and inhibitory descending pathways. Chronic hyperglycemia plays a central role by activating metabolic pathways such as the polyol pathway, leading to depletion of antioxidant defenses, increased oxidative and nitrosative stress, and accumulation of advanced glycation end products, all of which contribute to neuronal injury. Microvascular dysfunction further exacerbates nerve damage by causing ischemia, reduced perfusion, and hypoxia within the endoneurium, resulting in axonal degeneration and demyelination. In parallel, changes in ion channel expression particularly upregulation of voltage-gated sodium channels and dysregulation of calcium and potassium channels lead to neuronal hyperexcitability and abnormal pain signaling. Peripheral nerve injury also triggers activation of glial cells, promoting the release of pro-inflammatory cytokines and amplifying neuroinflammation. At the central level, sensitization of spinal neurons and enhanced glutamatergic signaling, along with reduced inhibitory GABAergic activity, contribute to heightened pain perception.
Diagnosis and management of DNP remain challenging due to incomplete understanding of its pathophysiology and limited disease-modifying therapies. Diagnosis is primarily clinical, involving a detailed history of symptoms such as burning, tingling, or shooting pain, along with neurological examination to assess sensory loss, reflexes, and nerve function, while excluding other causes of peripheral neuropathy. In some cases, nerve conduction studies or quantitative sensory testing may be used to confirm the diagnosis. Management begins with optimizing glycemic control and addressing lifestyle factors to slow disease progression. Pharmacological treatment is the mainstay, with first-line agents including anticonvulsants (pregabalin, gabapentin) and antidepressants (duloxetine, tricyclic antidepressants), which help reduce pain and improve sleep and quality of life. However, pain relief is often partial, with about 50% reduction considered successful. Opioids such as tramadol and tapentadol are reserved as second- or third-line options due to safety concerns. Topical therapies like capsaicin and lidocaine patches provide localized relief with fewer systemic effects. Adjunct treatments such as alpha-lipoic acid may offer additional benefits through antioxidant effects.
"Diabetic Neuropathic Pain - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathic Pain pipeline landscape is provided which includes the disease overview and Diabetic Neuropathic Pain treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Neuropathic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Neuropathic Pain.Diabetic Neuropathic Pain Emerging Drugs Chapters
This segment of the Diabetic Neuropathic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Diabetic Neuropathic Pain Emerging Drugs
- LX-9211: Lexicon Pharmaceuticals
- LY4065967: Eli Lilly and Company
- YJ001: Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Further product details are provided in the report……..
Diabetic Neuropathic Pain: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Neuropathic Pain drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Diabetic Neuropathic Pain
- There are approx. 10+ key companies which are developing the therapies for Diabetic Neuropathic Pain. The companies which have their Diabetic Neuropathic Pain drug candidates in the mid stage, i.e. phase II include, Lexicon Pharmaceuticals.
Phases
The report covers around 12+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Diabetic Neuropathic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Diabetic Neuropathic Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Neuropathic Pain therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Neuropathic Pain drugs.Diabetic Neuropathic Pain Report Insights
- Diabetic Neuropathic Pain Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Diabetic Neuropathic Pain Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Neuropathic Pain drugs?
- How many Diabetic Neuropathic Pain drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Neuropathic Pain?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Neuropathic Pain therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Neuropathic Pain and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Lexicon Pharmaceuticals
- Eli Lilly and Company
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Jemincare
Key Products
- LX-9211
- LY4065967
- YJ001
- HRS-2129
- JMKX000623
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryDiabetic Neuropathic Pain- Analytical PerspectiveDiabetic Neuropathic Pain Key CompaniesDiabetic Neuropathic Pain Key ProductsDiabetic Neuropathic Pain- Unmet NeedsDiabetic Neuropathic Pain- Market Drivers and BarriersDiabetic Neuropathic Pain- Future Perspectives and ConclusionDiabetic Neuropathic Pain Analyst ViewsDiabetic Neuropathic Pain Key CompaniesAppendix
Diabetic Neuropathic Pain: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug name: Company name
Mid Stage Products (Phase II)
LX-9211: Lexicon Pharmaceuticals
Early Stage Products (Phase I)
YJ001: Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Lexicon Pharmaceuticals
- Eli Lilly and Company
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Jemincare
